
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Vedanta Biosciences today announced the publication of additional results from the Phase 2 CONSORTIUM study for its lead candidate, VE303, which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI). The new analyses were published […]